A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours - Concepedia

Concepedia

Publication | Open Access

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

DOI Full Paper Access

93

Citations

13

References

2017

Year

Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, Amita Patnaik, Drew Rasco, R. Donald Harvey, Patricia LoRusso, Jasgit C. Sachdev, Giovanni Abbadessa, Ronald E. Savage,

British Journal of Cancer

Abstract

ARQ 087 had manageable toxicity at the RP2D of 300 mg QD, showed pharmacodynamics effects, and achieved objective responses, notably in patients with FGFR2 genetic alterations.

References

	Year	Citations

Page 1